Literature DB >> 28959910

A systematic review of pharmacoeconomic guidelines.

Ye Zhao1, Hai-Ming Feng2, Ji Qu2, Xiu Luo3, Wen-Juan Ma1, Jin-Hui Tian1,4.   

Abstract

OBJECTIVE: To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological development of PE guidelines.
MATERIALS AND METHODS: The authors performed a search for PE guidelines using PubMed, the Cochrane library database, and the websites of the International Society for Pharmacoeconomics and Outcomes Research. Information of each guideline was extracted using a pre-designed extraction template, which included 22 aspects; the guidelines were summarized in the forms of charts, and their characteristics have been described.
RESULTS: A total of 40 PE guidelines were studied. The most common methodological issues include the types of analysis, sources for effectiveness, use of quality-adjusted life-years (QALYs) to measure outcomes, and use of incremental cost effectiveness ratios to present results. The majority of the guidelines preferred a cost utility analysis with outcomes expressed in terms of QALYs. Most of the guidelines preferred meta-analysis or meta-analysis of the randomized controlled trials, and required a systematic review of all evidence. Issues that varied most in the guidelines were the choice of the comparator, recommended costs to be included, methods related to indirect cost calculations, methods of sensitivity analysis, and discounting rate.
CONCLUSION: A comparison of these guidelines revealed that a number of differences exist among them in several key aspects, and some critical methodological issues still exist, for which no best solution is available. Furthermore, efforts need to be made to develop harmonious methods for the PE, and to improve the transferability of the outcomes of PE evaluations.

Keywords:  Pharmacoeconomics; characteristics; comparison; guidelines

Mesh:

Year:  2017        PMID: 28959910     DOI: 10.1080/13696998.2017.1387118

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  6 in total

1.  Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.

Authors:  Hamraz Mokri; Ingelin Kvamme; Linda de Vries; Matthijs Versteegh; Pieter van Baal
Journal:  Eur J Health Econ       Date:  2022-08-04

2.  The Primary Process and Key Concepts of Economic Evaluation in Healthcare.

Authors:  Younhee Kim; Yunjung Kim; Hyeon-Jeong Lee; Seulki Lee; Sun-Young Park; Sung-Hee Oh; Suhyun Jang; Taejin Lee; Jeonghoon Ahn; Sangjin Shin
Journal:  J Prev Med Public Health       Date:  2022-08-24

3.  Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Yitian Lang; Deshi Dong
Journal:  Cancer Manag Res       Date:  2020-11-06       Impact factor: 3.989

4.  Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Yitian Lang; Deshi Dong; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-10-23       Impact factor: 2.859

5.  Trends and frontiers of research on pharmacoeconomics from 2012-2021: a scientometric analysis.

Authors:  Yan Liu; Zhenyan Bo; Dan Liu; Sha Diao; Chunsong Yang; Hailong Li; Linan Zeng; Qin Yu; Lingli Zhang
Journal:  Ann Transl Med       Date:  2022-03

Review 6.  Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.

Authors:  Abdulaziz Ibrahim Alzarea; Yusra Habib Khan; Abdullah Salah Alanazi; Muhammad Hammad Butt; Ziyad Saeed Almalki; Abdullah K AlAhmari; Saud Alsahali; Tauqeer Hussain Mallhi
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.